Preventing Oxidative Stress-induced Ischemic Injury- and Systemic Inflammation Complications During and After Invasive Cardiac Surgery With Alkaline Phosphatase (APPIRED III)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 08 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Apr 2024 Planned End Date changed from 31 Dec 2025 to 31 Mar 2026.
30 Aug 2023 New trial record
24 Aug 2023 According to Alloksys media release, after conducting the planned phase III trial, of which enrollment is expected to commence in Q3 2023, the company plans, preferably with a strategic partner, to prepare a New Drug Application (NDA) and/or Marketing Authorization Application (MAA) for RESCAP in the US and/or EEA, followed by introduction to the market as a critical care medicine.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com